OOIR: Observatory of International Research

Papers

(The H4-Index of Oncoimmunology is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer	98
Identification of pyroptosis-related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in colorectal cancer	93
Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies	75
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer	72
PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity	70
IFN-γ-induced ER stress impairs autophagy and triggers apoptosis in lung cancer cells	67
Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer	64
Ferroptosis becomes immunogenic: implications for anticancer treatments	61
YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non–small-cell lung cancer	61
Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative breast cancer	60
Exosome-mediated communication between tumor cells and tumor-associated macrophages: implications for tumor microenvironment	59
Lipid-associated macrophages in the tumor-adipose microenvironment facilitate breast cancer progression	57
YKT6 , as a potential predictor of prognosis and immunotherapy response for oral squamous cell carcinoma, is related to cell invasion, metastasis, and CD8+ T cell infiltration	54
Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study	53
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma	49
Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity	47
Integrated analyses of m ¹ A regulator-mediated modification patterns in tumor microenvironment-infiltrating immune cells in colon cancer	46
TIGIT ⁺ TIM-3 ⁺ NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related	45
Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer	44
The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis	44
Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients	41
Trial watch: intratumoral immunotherapy	41
Tumors exploit CXCR4 ^hi CD62L ^lo aged neutrophils to facilitate metastatic spread	39
Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma	39
Gas plasma irradiation of breast cancers promotes immunogenicity, tumor reduction, and an abscopal effect in vivo	39

Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors	38
Chronic stress promotes breast carcinoma metastasis by accumulating myeloid-derived suppressor cells through activating β-adrenergic signaling	38
Association between immune-related adverse event timing and treatment outcomes	38
Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness	38
Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis	37
Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice	37
A multicenter characterization of hepatitis associated with immune checkpoint inhibitors	37
Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry	37
Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer	36
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression	36
Re-polarization of immunosuppressive macrophages to tumor-cytotoxic macrophages by repurposed metabolic drugs	36